Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.

Bridgewater, New Jersey Saturday, October 18, 2025, 18:00 Hrs [IST] ...

On October 17, 2025, Insmed announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of BRINSUPRI for non-cystic ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

A chronic cough can be due to many things from asthma to post-COVID-19. Here's how to figure out why you can't stop coughing ...

ERS issues new bronchiectasis guidelines to improve patient care, standardise treatment, and reduce variability in global ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and devastating neurodegenerative disorder, at his clinic at the University of Alabama at Birmingham. But last ...